Last quarter (Q2 2022), ImmuPharma's total revenue was $―, a decrease of ― from the same quarter last year. In Q2, ImmuPharma's net income was $―. See ImmuPharma’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Dec 23	Dec 22	Dec 21	Dec 20	Dec 19
Total Revenue	$ ―	$ ―	$ ―	$ 118.35K	$ 126.67K	$ 77.92K
Cost of Revenue	$ ―	$ ―	$ ―	$ ―	$ ―	$ ―
Gross Profit	$ ―	$ ―	$ ―	$ ―	$ ―	$ ―
Operating Expense	$ ―	$ 3.18M	$ 3.03M	$ 5.28M	$ 5.72M	$ 6.36M
Operating Income	$ ―	$ -3.18M	$ -3.03M	$ -5.16M	$ -5.59M	$ -6.28M
Net Non Operating Interest Income Expense	$ ―	$ 3.02K	$ 247.94K	$ 205.25K	$ 395.02K	$ -1.70K
Other Income Expense	$ ―	$ 474.45K	$ -1.22M	$ ―	$ ―	$ ―
Pretax Income	$ ―	$ -3.66M	$ -1.54M	$ -8.94M	$ -7.25M	$ -6.74M
Tax Provision	$ ―	$ 497.10K	$ 648.90K	$ -766.81K	$ -386.25K	$ -620.77K
Earnings From Equity Interest Net Of Tax	$ ―	$ -354.57K	$ 1.22M	$ ―	$ ―	$ ―
Net Income Common Stockholders	$ ―	$ -4.16M	$ -2.19M	$ -8.17M	$ -6.86M	$ -6.12M
Basic EPS	$ ―	$ -0.01	$ -0.01	$ -0.03	$ -0.03	$ -0.04
Diluted EPS	$ ―	$ -0.01	$ -0.01	$ -0.03	$ -0.03	$ -0.04
Basic Average Shares	$ ―	$ 362.00M	$ 302.91M	$ 251.16M	$ 200.18M	$ 153.45M
Diluted Average Shares	$ ―	$ 362.00M	$ 302.91M	$ 251.16M	$ 200.18M	$ 153.45M
Dividend Per Share	$ ―	$ ―	$ ―	$ ―	$ ―	$ ―
Total Operating Income As Reported	$ ―	$ ―	$ ―	$ ―	$ ―	$ ―
Reported Normalized Basic E P S	$ ―	$ ―	$ ―	$ ―	$ ―	$ ―
Reported Normalized Diluted E P S	$ ―	$ ―	$ ―	$ ―	$ ―	$ ―
Rent Expense Supplemental	$ ―	$ ―	$ ―	$ ―	$ ―	$ ―
Total Expenses	$ ―	$ 3.18M	$ 3.03M	$ -5.28M	$ -5.72M	$ -6.36M
Net Income From Continuing And Discontinued Operation	$ ―	$ -4.16M	$ -2.19M	$ -8.17M	$ -6.86M	$ -6.12M
Normalized Income	$ ―	$ -2.74M	$ -1.25M	$ -8.28M	$ -7.63M	$ -7.37M
Interest Expense	$ ―	$ ―	$ ―	$ ―	$ ―	$ ―
EBIT	$ ―	$ -3.66M	$ -1.76M	$ -8.82M	$ -7.02M	$ -6.74M
EBITDA	$ ―	$ -3.66M	$ -1.76M	$ -8.70M	$ -6.84M	$ -6.74M

Currency in USD

ImmuPharma Earnings and Revenue History

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing